1. Home
  2. ACIU vs ESEA Comparison

ACIU vs ESEA Comparison

Compare ACIU & ESEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • ESEA
  • Stock Information
  • Founded
  • ACIU 2003
  • ESEA 2005
  • Country
  • ACIU Switzerland
  • ESEA Greece
  • Employees
  • ACIU N/A
  • ESEA N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • ESEA Marine Transportation
  • Sector
  • ACIU Health Care
  • ESEA Consumer Discretionary
  • Exchange
  • ACIU Nasdaq
  • ESEA Nasdaq
  • Market Cap
  • ACIU 332.4M
  • ESEA 293.8M
  • IPO Year
  • ACIU 2016
  • ESEA 2006
  • Fundamental
  • Price
  • ACIU $3.20
  • ESEA $39.07
  • Analyst Decision
  • ACIU Strong Buy
  • ESEA Buy
  • Analyst Count
  • ACIU 2
  • ESEA 1
  • Target Price
  • ACIU $12.00
  • ESEA $53.00
  • AVG Volume (30 Days)
  • ACIU 144.4K
  • ESEA 41.3K
  • Earning Date
  • ACIU 11-05-2024
  • ESEA 11-20-2024
  • Dividend Yield
  • ACIU N/A
  • ESEA 6.13%
  • EPS Growth
  • ACIU N/A
  • ESEA 3.12
  • EPS
  • ACIU N/A
  • ESEA 16.28
  • Revenue
  • ACIU $48,505,404.00
  • ESEA $208,648,067.00
  • Revenue This Year
  • ACIU $85.33
  • ESEA $13.93
  • Revenue Next Year
  • ACIU $80.69
  • ESEA $5.41
  • P/E Ratio
  • ACIU N/A
  • ESEA $2.43
  • Revenue Growth
  • ACIU 4097200.00
  • ESEA 13.90
  • 52 Week Low
  • ACIU $2.25
  • ESEA $26.20
  • 52 Week High
  • ACIU $5.14
  • ESEA $50.92
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 47.84
  • ESEA 41.61
  • Support Level
  • ACIU $3.16
  • ESEA $37.37
  • Resistance Level
  • ACIU $3.48
  • ESEA $40.95
  • Average True Range (ATR)
  • ACIU 0.20
  • ESEA 1.76
  • MACD
  • ACIU -0.01
  • ESEA -0.10
  • Stochastic Oscillator
  • ACIU 12.82
  • ESEA 27.96

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

Share on Social Networks: